Press Releases
Upcoming Events
May 31 - Jun 04, 2024
Abstract Selected for Late-Breaking Oral Presentation
- June 3, 2024 | 8:00 AM - 9:30 AM CT
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients
Abstract: 6015 | Rapid Oral Abstract Session - Head and Neck Cancer
Abstracts Selected for Poster Presentation
- June 2, 2024 | 9:00 AM - 12:00 PM CT
Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer
Abstract: 6124 | Poster Session - Head and Neck Cancer - June 3, 2024 | 9:00 AM - 12:00 PM CT
A Phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer
Abstract 5623 | Poster Session - Gynecologic Cancer
Chicago, Illinois
Media Kit
Precigen maintains a media kit with our corporate logo and our CEO’s headshot and bio that can be used by media for editorial purposes. Should you have any questions or seek assets not included in our media kit, please contact:
Download
Media Kit
Media Kit